Last year's DGI conference (German Association of Oral Implantology) in Frankfurt marked the launch of another two implant types onto the highly competitive dental implantology market. BEGO Semados^® RS and RSX implants are marketed all over Europe. Six months after the launch: An ideal time for a first review.

"We are very satisfied with the sales trend. With over 20,000 implants sold, our expectations have been surpassed by far. The RSX-Line in particular is becoming increasingly popular amongst our users as an attractive alternative to the established products from various premium suppliers," said Walter Esinger, Managing Director of BEGO Implant Systems.

"In addition to the sales figures, the shifts in our implant portfolio are also interesting. There has undoubtedly been a move from BEGO Semados^® S implants to the new RS and RSX implants but, ultimately, the conversion is on a healthy scale. The sales of BEGO Semados^® RI-Line implants, on the other hand, have been virtually unaffected by the launch of the new implants thus far," explained Dipl.?Ing. André Henkel, Product Manager at BEGO Implant Systems. "We are especially pleased at the large number of new customers and interested parties," Henkel continued.

The BEGO Semados^® S implant is still unquestionably the reliable all-rounder in the BEGO Implant Systems portfolio whilst, with its self-condensing thread, the BEGO Semados^® RI implant remains the means of choice for many when faced with difficult bone conditions.

"On the whole, we feel vindicated: With the new implant product portfolio from BEGO Implant Systems, we are able to completely satisfy individual requirements in terms of both patient treatment and user preferences," explained Esinger.

The complementary prosthodontic line, which picks up on and supports the platform switch concept of the new implants, will be available towards the end of the second quarter. Nevertheless, all prosthetic components which are available today and which are fully compatible with all family members (S/RI/RS/RSX) will still form part of our range. Integration of the new platform switch abutments in the CAD/CAM service portfolio of BEGO Medical GmbH is also expected by the end of the second quarter.

The international roll-out, particularly in markets subject to strict regulations, is planned for the second half of 2014.